The Gerson Therapy: Juicing, Coffee Enemas & Metabolic Healing
Developed by Dr. Max Gerson in the 1920s, this intensive nutritional protocol has been used by thousands seeking to reverse chronic disease and cancer.
Two antiparasitic drugs — one veterinary, one human — have generated extraordinary interest in the cancer research community. Here's what the science actually shows.
Antiparasitic drugs as cancer treatments are an area of preclinical research interest. No randomised controlled trials have established efficacy or safety for this use in humans.
For educational purposes only — not medical advice. How we evaluate evidence →
Antiparasitic drugs as cancer treatments are an area of early preclinical research. No randomised controlled trials have established efficacy or safety for this use in humans. These are not approved cancer therapies.
This article examines the hypothesis and the laboratory evidence — not a treatment recommendation.
Always consult a qualified physician or oncologist before making any changes to your treatment plan. This article is for informational purposes only and does not constitute medical advice, a diagnosis, or a treatment recommendation.
Reviewed by
Dr. A. Ferreira, MDGeneral practitioner with integrative medicine training. Reviewed for factual accuracy and safety information. These drugs are not approved cancer treatments; this article covers preclinical research only.
Last reviewed
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Our editorial standards →
Few topics in alternative oncology have generated as much grassroots interest — and as much controversy — as the repurposing of antiparasitic drugs for cancer treatment. Ivermectin, a human antiparasitic used globally for river blindness and other parasitic infections, and fenbendazole, a veterinary dewormer used in dogs and livestock, have both attracted significant attention following anecdotal reports of remarkable cancer remissions and a growing body of preclinical research suggesting genuine anticancer mechanisms.
Fenbendazole: The Joe Tippens Story. The modern fenbendazole-cancer story begins with Joe Tippens, a man diagnosed with small-cell lung cancer in 2016 and given three months to live. Tippens experienced a complete remission and attributed it to a self-initiated protocol that included fenbendazole (a dog dewormer), curcumin, CBD oil, and vitamin E succinate. His story sparked a global wave of interest — particularly in South Korea, where it became a national phenomenon. A critical detail often omitted in retellings: Tippens was also enrolled in a clinical trial of pembrolizumab (Keytruda), a checkpoint inhibitor immunotherapy, at the time of his remission. His oncologists have noted that pembrolizumab alone can produce complete remissions in a small percentage of small-cell lung cancer patients. It is not possible to determine from a single case report which element — or combination — was responsible for his outcome. This is the fundamental limitation of anecdotal evidence: confounders cannot be controlled.
The Mechanism: Microtubule Disruption. Fenbendazole belongs to the benzimidazole class of drugs, which work by binding to tubulin — the protein that forms microtubules, the structural scaffolding of cells. In parasites, this disrupts the cytoskeleton and kills the organism. Cancer cells, which depend on intact microtubules for cell division (mitosis), are also vulnerable to this mechanism. Preclinical studies have shown fenbendazole to inhibit glucose uptake in cancer cells (by downregulating GLUT transporters), induce apoptosis, and inhibit tumor growth in multiple cancer cell lines and animal models.
Ivermectin has demonstrated multiple anticancer mechanisms in preclinical research: inhibition of the WNT-TCF signaling pathway (involved in cancer stem cell maintenance), induction of mitochondrial dysfunction in cancer cells, inhibition of the PAK1 kinase (involved in tumor growth and metastasis), and immunomodulatory effects that may enhance anti-tumor immune responses. A 2020 review in Pharmacological Research catalogued over 30 preclinical studies demonstrating anticancer activity across multiple cancer types.
The Clinical Evidence Gap. The critical limitation of both fenbendazole and ivermectin as cancer treatments is the complete absence of randomised controlled trial data in humans. All the evidence is preclinical — cell culture and animal studies — with a handful of case reports and small observational studies. Neither drug has been established as an effective cancer treatment. The leap from 'kills cancer cells in a petri dish' to 'treats cancer in humans' is enormous and frequently underestimated: multiple drugs that show spectacular preclinical anticancer activity have failed in clinical trials. Using either drug as a cancer treatment outside of a clinical trial is off-label use that carries unknown risks, and doing so in place of conventional treatment can result in delayed access to therapies with established efficacy.
Personalised plan
Build a personalised plan for long-term health and prevention.
Seen a claim you want to verify?
The Claim Decoder grades the evidence behind any natural health claim — A to F, with sources.
Suggested from this article:
"High-dose vitamin C can treat cancer"
Prompted by: Ivermectin & Fenbendazole: The Antiparasitic Cancer Hypothesis
Developed by Dr. Max Gerson in the 1920s, this intensive nutritional protocol has been used by thousands seeking to reverse chronic disease and cancer.
Dr. Johanna Budwig's controversial protocol combining flaxseed oil and cottage cheese has attracted devoted followers for 70 years. What does the science say?
Essiac tea — a blend of four herbs from Ojibwe tradition — has been used as a cancer remedy since the 1920s. Here's the history and the evidence.